CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs ...

Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...

SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene”) (Nasdaq: ADAG), a company ...

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors�reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

CTLA-4 dimer affinity increases by over 10 times versus that of the monomer, making it far more useful in screening and drug validation. This is due to CTLA-4 being expressed as a dimer under ...

In the fourth episode of a six-part interview series on immunotherapy, Marc Voigt, CEO and Executive Director of Immutep (ASX ...

European Commission approves Bristol Myers Squibb’s Opdivo plus Yervoy for first-line treatment of adult patients with unresectable or advanced HCC: Princeton, New Jersey Monday ...